Indications › Obesity & overweight

GLP‑1 drugs in obesity & overweight

Which incretin agents are being studied in obesity & overweight, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.

Trials on file

453

Active

210

Results scheduled

113

Molecules studied

17

Sponsors

200

FDA-approved for obesity & overweight: liraglutide · orforglipron · semaglutide · tirzepatide. Approval wording is on each drug page, quoted from the label.

4 of the molecules tracked here are FDA-approved for obesity & overweight, so the trials below are asking further questions rather than establishing whether the class works at all. 335 of the 453 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 118 still in early phases. 200 distinct sponsors are involved, 223 of the trials run commercially and the rest by universities and hospitals.

Molecules studied in this indication

VK2735 · aleniglipron · cagrilintide · danuglipron · dulaglutide · ecnoglutide · exenatide in this indication · liraglutide in this indication · maridebart cafraglutide in this indication · mazdutide in this indication · olatorepatide · orforglipron in this indication · petrelintide · retatrutide in this indication · semaglutide in this indication · survodutide · tirzepatide in this indication

Results due in this indication

Trials on file

All 453 incretin trials recorded in this indication, active first.